PRF Technologies Ltd.

What they do

The company is an Israeli-domiciled registrant that files with the SEC on Form 20-F and reports in U.S. dollars under U.S. GAAP. Its operations are pharmaceutical development, specifically prolonged-release local anesthetic products intended to reduce reliance on opioids after surgery. It is pre-commercial: the 20-F reports only a de minimis revenue figure for 2025 and no revenue in 2023 or 2024.

Revenue drivers

• Prolonged-release post-operative pain product candidates — The company's business is the development of injectable, prolonged-release formulations for post-operative pain management; no product sales revenue is reported in the excerpts.
• Other revenue (2025 only) — XBRL data shows $17,000 of annual revenue in 2025 against $0.00 in 2024 and 2023, consistent with a company that has not yet commercialized its lead programs.

Recent performance

Fiscal 2025 net loss was $5.0 million, improved from a $14.6 million loss in 2024. Operating cash outflow was $4.0 million in 2025, down from $12.6 million in 2024. Diluted EPS was negative $7.47 for 2025 versus negative $105.52 for 2024. At December 31, 2025 the company reported total assets of $12.0 million, total liabilities of $2.7 million, shareholder equity of $8.5 million and cash and equivalents of $3.1 million. Revenue was nominal at $17,000 for the year.

Strategy

The company continues to fund development of its prolonged-release injectable pain programs while carrying no marketed product revenue of scale. Its loss and cash-burn trajectory improved in 2025 relative to 2024, but it remains dependent on external financing given cash and equivalents of $3.1 million at year-end. The 20-F notes a 1-for-10 reverse share split effected June 8, 2023, consistent with earlier capital-structure management. No further forward-looking priorities are specified in the excerpts provided.

Risks

• No commercial revenue — 2024 and 2023 revenue was $0.00 and 2025 revenue was only $17,000, so operations are funded by financing rather than product sales.
• Limited cash runway — Cash and equivalents of $3.1 million at December 31, 2025 against a $4.0 million operating cash outflow in 2025 implies a short funding horizon absent new capital.
• Accumulated losses — The company reported net losses every year from 2021 through 2025, including $9.3 million in 2023 and $14.6 million in 2024.
• Israeli operations and Nasdaq listing — As an Israel-incorporated company listed on Nasdaq, it faces jurisdiction-specific regulatory, tax and disclosure obligations, and its ordinary shares are subject to potential delisting and continued listing standards.

Outlook

The excerpts do not contain specific management guidance on future revenue, product timelines or financing plans. What the filings do show is a company whose 2025 losses and cash use narrowed versus 2024, but which ended 2025 with $3.1 million in cash and no meaningful revenue.